You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
DYRK1A/B inhibitor (IC50 values are 0.23 and 0.24 μM, for DYRK1B and DYRKA respectively). Binds at the ATP-binding cleft of the enzyme. Reverses aberrant tau-phosphorylation and rescues repressed calcineurin/NFAT signaling. Impairs the self-renewal capacity of subventricular zone neural stem cells. Also available as a prodrug, proINDY (Cat. No. 4998).
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 235.3. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.25 mL||21.25 mL||42.5 mL|
|5 mM||0.85 mL||4.25 mL||8.5 mL|
|10 mM||0.42 mL||2.12 mL||4.25 mL|
|50 mM||0.08 mL||0.42 mL||0.85 mL|
References are publications that support the biological activity of the product.
Pozo et al (2013) Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth. J.Clin.Invest. 123 2475 PMID: 23635774
Ogawa et al (2010) Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nat.Commun. 1 86 PMID: 20981014
If you know of a relevant reference for INDY, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: INDY, INDY supplier, INDY, downs, syndrome-related, kinase, Dyrk1A/B, inhibitors, inhibits, tau, phosphorylation, hyperphosphorylation, calcineurin, NFAT, signalling, self-renewal, neural, stem, cells, NSCs, Microtubules, Stem, Cell, Proliferation, DYRK, 4997, Tocris Bioscience
4 Citations for INDY
Citations are publications that use Tocris products. Selected citations for INDY include:
Kim et al (2016) A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition. Dis Model Mech 9 839 PMID: 27483355
Seu et al (2015) Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection. J Virol 89 6656 PMID: 25878110
Wang et al (2015) A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. Nat Med 21 383 PMID: 25751815
Wahl et al (2018) Transcriptome analysis of Xenopus orofacial tissues deficient in retinoic acid receptor function. BMC Genomics 19 795 PMID: 30390632
Do you know of a great paper that uses INDY from Tocris? Please let us know.
Reviews for INDY
There are currently no reviews for this product. Be the first to review INDY and earn rewards!
Have you used INDY?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.